52P: Does timing of immunotherapy infusion influence clinical outcomes in non-small cell lung cancer?
I. Furtado(Administração Regional de Saúde de Lisboa e Vale do Tejo), I. Guerreiro(Administração Regional de Saúde de Lisboa e Vale do Tejo), Rosa M. Quinta‐Ferreira(University of Coimbra), Sara Alfarroba(Administração Regional de Saúde de Lisboa e Vale do Tejo), Nádia Duarte(Administração Regional de Saúde de Lisboa e Vale do Tejo), J.L. Mendes, R. Escaleira(Administração Regional de Saúde de Lisboa e Vale do Tejo), M. Seladas(Administração Regional de Saúde de Lisboa e Vale do Tejo), Luís Coelho(Administração Regional de Saúde de Lisboa e Vale do Tejo), F. Verdasca(Administração Regional de Saúde de Lisboa e Vale do Tejo), M.A. Montenegro(Hospital de São José), A.J.S. Fernandes(Administração Regional de Saúde de Lisboa e Vale do Tejo)
Cited by 0
Related Papers
Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Rectum: A Case Report
|Case Reports in Oncology|2024|4
Male Breast Cancer in Portugal: A Descriptive Analysis of a 20-Year Cohort
|European Journal of Breast Health|2025|2
P-191 Ampullary neoplasms – how to treat in real-world practice? A retrospective study
|Annals of Oncology|2022|0
P-351 Colon cancer in young patients – real-world data from a single center review
|Annals of Oncology|2023|0
Neoadjuvant cisplatin-based chemotherapy (NAC) in Muscle-invasive bladder cancer (MIBC): Real-world data
|European Urology Open Science|2023|0